linguistic:paraphrasing, information:filtering
Immunoprophylaxis

Nirsevimab (Beyfortus) is another antiviral monoclonal antibody, that has been approved for the prevention of RSV lower respiratory tract disease in newborns and infants during their first RSV season. Nirsevimab requires only one dose that lasts the entire RSV season, unlike palivizumab, which has to be injected about once a month for up to four times to remain effective. Nirsevimab was approved for medical use in the European Union and the United Kingdom in November 2022, and in Canada in April 2023.